This test was discontinued on 7/6/2026 and replaced with Somatic Disease RNA Sequencing (test code: SDRNA). However, Solid Tumor Fusion Analysis is New York State Approved and may still be ordered for New York State patients. Please discuss with the laboratory if there are other testing needs related to this assay.
| Specimen Type | Type of Container | Volume of Specimen | Status |
|---|---|---|---|
| Tissue (Snap-frozen) | Tissue cassette | 50 mg | Preferred |
| Tissue (Snap-frozen) | Cryogenic tube | 50 mg | Alternate |
| OCT-embedded tissue | Tissue cassette | 50 mg | Preferred |
| OCT-embedded tissue | Cryogenic tube | 50 mg | Alternate |
| Paraffin embedded tissue | Paraffin block | Preferred | |
| Tissue (Fresh) | Tissue culture transport media | 50 mg | Preferred |
| Tissue (Fresh) | Sterile container with saline | 50 mg | Alternate |
| Tissue scrolls (FFPE) | Sterile container | Preferred | |
| Unstained tissue slides | Unstained slides and consecutive cut H&E | 10 slides, 10 microns thick | Alternate |
| RNA *Must be extracted in CLIA approved lab | Microcentrifuge tube | Contact IGM lab | Alternate |
If you are an external healthcare provider with no access to Nationwide Children’s Epic system, submission of a completed Oncology Genetic Test Requisition Form is required. If you are an internal ordering provider with access to Nationwide Children’s Epic system, no requisition form is required; please place the lab order electronically in Epic.
If submitting tissue scroll specimen, please use this Tissue Scroll Calculator tool to determine the thickness and number of tissue scrolls to send to the laboratory (approximately 300mm2 at 10 microns thickness).
SPECIMEN INFORMATION:
Fresh and snap-frozen tissue specimens must contain minimum of 10% tumor. Formalin-fixed paraffin embedded (FFPE) tissue block and FFPE tissue scroll specimens must contain minimum of 25% tumor. Please submit the pathology report from the submitted sample. Internal pathology review will also be performed to determine the tumor content in specimen.
If sending FFPE tissue scrolls, an H&E slide from a consecutive cut is also required. Please contact the laboratory at (614) 722-5321 to request the scroll calculator application to be emailed to you to determine the number of scrolls required.
All specimens must be labeled with a patient name and one other identifier (DOB, MRN, Specimen ID#, etc). Sample acquisition prior to receiving therapy is strongly preferred.
SPECIMEN SHIPPING:
Specimens must be shipped as soon as possible after collection due to time-sensitive specimen stability. Ship all samples via overnight courier. Whenever possible, send specimen immediately after collection. For fresh tumor tissue, ship the sample refrigerated using cold packs. If specimen cannot be sent on the collection date, then snap-freeze the tumor tissue immediately after collection and ship the sample frozen (bury the entire tissue in dry ice). Lab must receive specimen within 48 hours. FFPE tissue and FFPE tissue scrolls should be sent at room temperature via overnight shipping. Saturday deliveries are accepted; please check Saturday Delivery on shipment labels.
This test evaluates for the presence of oncogenic gene fusions in solid tumors. Gene fusions seen in cancers frequently involve tyrosine kinases where constitutive activation results in augmented downstream signaling and tumor proliferation. Targeted therapies directed at constitutively-activated oncogenic tyrosine kinases have been demonstrated to be effective against cancers with fusions involving certain genes, such as ALK, ROS1, PDGFB, RET, NTRK1, NTRK2, NTRK3, FGFR1, FGFR2, FGFR3, BRAF, and CRAF. Identifying a specific oncogenic fusion present in the patient offers an opportunity to treat the patient with inhibitors specific to the oncogenic fusion present in the patient.
This test provides fusion information for 151 gene fusion partners relevant to solid tumors, including those associated with soft tissue sarcomas (see below for the list of fusion partner genes included in this test):
ABL1, ABL2, ACVR2A, AKT1, AKT2, AKT3, ALK, AR, ARHGAP26, ARHGAP6, AXL, BCOR, BRAF, BRD3, BRD4, C11orf95, CAMTA1, CCNB3, CCND1, CD274, CIC,CREB3L2, CRTC1, CSF1, CSF1R, CTNNB1, DNAJB1, EGF, EGFR, EPC1, ERBB2, ERBB4, ERG, ESR1, ESRRA, ETV1, ETV4, ETV5, ETV6, EWSR1, FGF1, FGFR1, FGFR2, FGFR3, FGR, FOS, FOSB, FOXO1, FOXO4, FOXR2, FUS, GLI1, GRB7, HMGA2, HRAS, HTN3, IDH1, IDH2, IGF1R, INSR, JAK1, JAK2, JAK3, JAZF1, KIT, KRAS, MAML1, MAML2, MAML3, MAP2K1, MAST1, MAST2, MBTD1, MDM2, MEAF6 ,MET, MGEA5, MKL2, MN1, MSANTD3, MSMB, MUSK, MYB, MYBL1, MYC, MYOD1, NCOA1, NCOA2, NCOA3, NDRG1, NFATC2, NFE2L2, NFIB, NOTCH1, NOTCH2, NR4A3, NRAS, NRG1, NTRK1, NTRK2, NTRK3, NUMBL, NUTM1, PAX3, PAX7, PAX8, PDGFB, PDGFD, PDGFRA, PDGFRB, PHF1, PHKB, PIK3CA, PKN1, PLAG1, PPARG, PRDM10, PRKACA, PRKACB, PRKCA, PRKCB, PRKCD, PRKD1, PRKD2, PRKD3, QKI, RAD51B, RAF1, RELA, RET, ROS1, RSPO2, RSPO3, SETD2, SS18, SS18L1, STAT6, TAF15, TCF12, TERT, TFE3, TFEB, TFG, THADA, TMPRSS2, TTYH1, USP6, VGLL2, WWTR1, YAP1, YWHAE |
Positive results may be confirmed by RT-PCR with Sanger sequencing.
This test was discontinued on 7/6/2026 and replaced with Somatic Disease RNA Sequencing (test code: SDRNA). However, Solid Tumor Fusion Analysis is New York State Approved and may still be ordered for New York State patients. Please discuss with the laboratory if there are other testing needs related to this assay.
| Specimen Type | Type of Container | Volume of Specimen | Status |
|---|---|---|---|
| Tissue (Snap-frozen) | Tissue cassette | 50 mg | Preferred |
| Tissue (Snap-frozen) | Cryogenic tube | 50 mg | Alternate |
| OCT-embedded tissue | Tissue cassette | 50 mg | Preferred |
| OCT-embedded tissue | Cryogenic tube | 50 mg | Alternate |
| Paraffin embedded tissue | Paraffin block | Preferred | |
| Tissue (Fresh) | Tissue culture transport media | 50 mg | Preferred |
| Tissue (Fresh) | Sterile container with saline | 50 mg | Alternate |
| Tissue scrolls (FFPE) | Sterile container | Preferred | |
| Unstained tissue slides | Unstained slides and consecutive cut H&E | 10 slides, 10 microns thick | Alternate |
| RNA *Must be extracted in CLIA approved lab | Microcentrifuge tube | Contact IGM lab | Alternate |
| Specimen Type | Type of Container | Minimum Volume |
|---|---|---|
| Tissue (Snap-frozen) | Tissue cassette | |
| Tissue (Snap-frozen) | Cryogenic tube | |
| OCT-embedded tissue | Tissue cassette | |
| OCT-embedded tissue | Cryogenic tube | |
| Paraffin embedded tissue | Paraffin block | |
| Tissue (Fresh) | Tissue culture transport media | |
| Tissue (Fresh) | Sterile container with saline | |
| Tissue scrolls (FFPE) | Sterile container |
If you are an external healthcare provider with no access to Nationwide Children’s Epic system, submission of a completed Oncology Genetic Test Requisition Form is required. If you are an internal ordering provider with access to Nationwide Children’s Epic system, no requisition form is required; please place the lab order electronically in Epic.
If submitting tissue scroll specimen, please use this Tissue Scroll Calculator tool to determine the thickness and number of tissue scrolls to send to the laboratory (approximately 300mm2 at 10 microns thickness).
SPECIMEN INFORMATION:
Fresh and snap-frozen tissue specimens must contain minimum of 10% tumor. Formalin-fixed paraffin embedded (FFPE) tissue block and FFPE tissue scroll specimens must contain minimum of 25% tumor. Please submit the pathology report from the submitted sample. Internal pathology review will also be performed to determine the tumor content in specimen.
If sending FFPE tissue scrolls, an H&E slide from a consecutive cut is also required. Please contact the laboratory at (614) 722-5321 to request the scroll calculator application to be emailed to you to determine the number of scrolls required.
All specimens must be labeled with a patient name and one other identifier (DOB, MRN, Specimen ID#, etc). Sample acquisition prior to receiving therapy is strongly preferred.
SPECIMEN SHIPPING:
Specimens must be shipped as soon as possible after collection due to time-sensitive specimen stability. Ship all samples via overnight courier. Whenever possible, send specimen immediately after collection. For fresh tumor tissue, ship the sample refrigerated using cold packs. If specimen cannot be sent on the collection date, then snap-freeze the tumor tissue immediately after collection and ship the sample frozen (bury the entire tissue in dry ice). Lab must receive specimen within 48 hours. FFPE tissue and FFPE tissue scrolls should be sent at room temperature via overnight shipping. Saturday deliveries are accepted; please check Saturday Delivery on shipment labels.
This test evaluates for the presence of oncogenic gene fusions in solid tumors. Gene fusions seen in cancers frequently involve tyrosine kinases where constitutive activation results in augmented downstream signaling and tumor proliferation. Targeted therapies directed at constitutively-activated oncogenic tyrosine kinases have been demonstrated to be effective against cancers with fusions involving certain genes, such as ALK, ROS1, PDGFB, RET, NTRK1, NTRK2, NTRK3, FGFR1, FGFR2, FGFR3, BRAF, and CRAF. Identifying a specific oncogenic fusion present in the patient offers an opportunity to treat the patient with inhibitors specific to the oncogenic fusion present in the patient.
This test provides fusion information for 151 gene fusion partners relevant to solid tumors, including those associated with soft tissue sarcomas (see below for the list of fusion partner genes included in this test):
ABL1, ABL2, ACVR2A, AKT1, AKT2, AKT3, ALK, AR, ARHGAP26, ARHGAP6, AXL, BCOR, BRAF, BRD3, BRD4, C11orf95, CAMTA1, CCNB3, CCND1, CD274, CIC,CREB3L2, CRTC1, CSF1, CSF1R, CTNNB1, DNAJB1, EGF, EGFR, EPC1, ERBB2, ERBB4, ERG, ESR1, ESRRA, ETV1, ETV4, ETV5, ETV6, EWSR1, FGF1, FGFR1, FGFR2, FGFR3, FGR, FOS, FOSB, FOXO1, FOXO4, FOXR2, FUS, GLI1, GRB7, HMGA2, HRAS, HTN3, IDH1, IDH2, IGF1R, INSR, JAK1, JAK2, JAK3, JAZF1, KIT, KRAS, MAML1, MAML2, MAML3, MAP2K1, MAST1, MAST2, MBTD1, MDM2, MEAF6 ,MET, MGEA5, MKL2, MN1, MSANTD3, MSMB, MUSK, MYB, MYBL1, MYC, MYOD1, NCOA1, NCOA2, NCOA3, NDRG1, NFATC2, NFE2L2, NFIB, NOTCH1, NOTCH2, NR4A3, NRAS, NRG1, NTRK1, NTRK2, NTRK3, NUMBL, NUTM1, PAX3, PAX7, PAX8, PDGFB, PDGFD, PDGFRA, PDGFRB, PHF1, PHKB, PIK3CA, PKN1, PLAG1, PPARG, PRDM10, PRKACA, PRKACB, PRKCA, PRKCB, PRKCD, PRKD1, PRKD2, PRKD3, QKI, RAD51B, RAF1, RELA, RET, ROS1, RSPO2, RSPO3, SETD2, SS18, SS18L1, STAT6, TAF15, TCF12, TERT, TFE3, TFEB, TFG, THADA, TMPRSS2, TTYH1, USP6, VGLL2, WWTR1, YAP1, YWHAE |
Positive results may be confirmed by RT-PCR with Sanger sequencing.
This test evaluates for the presence of oncogenic gene fusions in solid tumors. Gene fusions seen in cancers frequently involve tyrosine kinases where constitutive activation results in augmented downstream signaling and tumor proliferation. Targeted therapies directed at constitutively-activated oncogenic tyrosine kinases have been demonstrated to be effective against cancers with fusions involving certain genes, such as ALK, ROS1, PDGFB, RET, NTRK1, NTRK2, NTRK3, FGFR1, FGFR2, FGFR3, BRAF, and CRAF. Identifying a specific oncogenic fusion present in the patient offers an opportunity to treat the patient with inhibitors specific to the oncogenic fusion present in the patient.
This test provides fusion information for 151 gene fusion partners relevant to solid tumors, including those associated with soft tissue sarcomas (see below for the list of fusion partner genes included in this test):
ABL1, ABL2, ACVR2A, AKT1, AKT2, AKT3, ALK, AR, ARHGAP26, ARHGAP6, AXL, BCOR, BRAF, BRD3, BRD4, C11orf95, CAMTA1, CCNB3, CCND1, CD274, CIC,CREB3L2, CRTC1, CSF1, CSF1R, CTNNB1, DNAJB1, EGF, EGFR, EPC1, ERBB2, ERBB4, ERG, ESR1, ESRRA, ETV1, ETV4, ETV5, ETV6, EWSR1, FGF1, FGFR1, FGFR2, FGFR3, FGR, FOS, FOSB, FOXO1, FOXO4, FOXR2, FUS, GLI1, GRB7, HMGA2, HRAS, HTN3, IDH1, IDH2, IGF1R, INSR, JAK1, JAK2, JAK3, JAZF1, KIT, KRAS, MAML1, MAML2, MAML3, MAP2K1, MAST1, MAST2, MBTD1, MDM2, MEAF6 ,MET, MGEA5, MKL2, MN1, MSANTD3, MSMB, MUSK, MYB, MYBL1, MYC, MYOD1, NCOA1, NCOA2, NCOA3, NDRG1, NFATC2, NFE2L2, NFIB, NOTCH1, NOTCH2, NR4A3, NRAS, NRG1, NTRK1, NTRK2, NTRK3, NUMBL, NUTM1, PAX3, PAX7, PAX8, PDGFB, PDGFD, PDGFRA, PDGFRB, PHF1, PHKB, PIK3CA, PKN1, PLAG1, PPARG, PRDM10, PRKACA, PRKACB, PRKCA, PRKCB, PRKCD, PRKD1, PRKD2, PRKD3, QKI, RAD51B, RAF1, RELA, RET, ROS1, RSPO2, RSPO3, SETD2, SS18, SS18L1, STAT6, TAF15, TCF12, TERT, TFE3, TFEB, TFG, THADA, TMPRSS2, TTYH1, USP6, VGLL2, WWTR1, YAP1, YWHAE |
Positive results may be confirmed by RT-PCR with Sanger sequencing.
This test was discontinued on 7/6/2026 and replaced with Somatic Disease RNA Sequencing (test code: SDRNA). However, Solid Tumor Fusion Analysis is New York State Approved and may still be ordered for New York State patients. Please discuss with the laboratory if there are other testing needs related to this assay.
| Specimen Type | Type of Container | Volume of Specimen | Status |
|---|---|---|---|
| Tissue (Snap-frozen) | Tissue cassette | 50 mg | Preferred |
| Tissue (Snap-frozen) | Cryogenic tube | 50 mg | Alternate |
| OCT-embedded tissue | Tissue cassette | 50 mg | Preferred |
| OCT-embedded tissue | Cryogenic tube | 50 mg | Alternate |
| Paraffin embedded tissue | Paraffin block | Preferred | |
| Tissue (Fresh) | Tissue culture transport media | 50 mg | Preferred |
| Tissue (Fresh) | Sterile container with saline | 50 mg | Alternate |
| Tissue scrolls (FFPE) | Sterile container | Preferred | |
| Unstained tissue slides | Unstained slides and consecutive cut H&E | 10 slides, 10 microns thick | Alternate |
| RNA *Must be extracted in CLIA approved lab | Microcentrifuge tube | Contact IGM lab | Alternate |
| Specimen Type | Type of Container | Minimum Volume |
|---|---|---|
| Tissue (Snap-frozen) | Tissue cassette | |
| Tissue (Snap-frozen) | Cryogenic tube | |
| OCT-embedded tissue | Tissue cassette | |
| OCT-embedded tissue | Cryogenic tube | |
| Paraffin embedded tissue | Paraffin block | |
| Tissue (Fresh) | Tissue culture transport media | |
| Tissue (Fresh) | Sterile container with saline | |
| Tissue scrolls (FFPE) | Sterile container |
If you are an external healthcare provider with no access to Nationwide Children’s Epic system, submission of a completed Oncology Genetic Test Requisition Form is required. If you are an internal ordering provider with access to Nationwide Children’s Epic system, no requisition form is required; please place the lab order electronically in Epic.
If submitting tissue scroll specimen, please use this Tissue Scroll Calculator tool to determine the thickness and number of tissue scrolls to send to the laboratory (approximately 300mm2 at 10 microns thickness).
SPECIMEN INFORMATION:
Fresh and snap-frozen tissue specimens must contain minimum of 10% tumor. Formalin-fixed paraffin embedded (FFPE) tissue block and FFPE tissue scroll specimens must contain minimum of 25% tumor. Please submit the pathology report from the submitted sample. Internal pathology review will also be performed to determine the tumor content in specimen.
If sending FFPE tissue scrolls, an H&E slide from a consecutive cut is also required. Please contact the laboratory at (614) 722-5321 to request the scroll calculator application to be emailed to you to determine the number of scrolls required.
All specimens must be labeled with a patient name and one other identifier (DOB, MRN, Specimen ID#, etc). Sample acquisition prior to receiving therapy is strongly preferred.
SPECIMEN SHIPPING:
Specimens must be shipped as soon as possible after collection due to time-sensitive specimen stability. Ship all samples via overnight courier. Whenever possible, send specimen immediately after collection. For fresh tumor tissue, ship the sample refrigerated using cold packs. If specimen cannot be sent on the collection date, then snap-freeze the tumor tissue immediately after collection and ship the sample frozen (bury the entire tissue in dry ice). Lab must receive specimen within 48 hours. FFPE tissue and FFPE tissue scrolls should be sent at room temperature via overnight shipping. Saturday deliveries are accepted; please check Saturday Delivery on shipment labels.
This test evaluates for the presence of oncogenic gene fusions in solid tumors. Gene fusions seen in cancers frequently involve tyrosine kinases where constitutive activation results in augmented downstream signaling and tumor proliferation. Targeted therapies directed at constitutively-activated oncogenic tyrosine kinases have been demonstrated to be effective against cancers with fusions involving certain genes, such as ALK, ROS1, PDGFB, RET, NTRK1, NTRK2, NTRK3, FGFR1, FGFR2, FGFR3, BRAF, and CRAF. Identifying a specific oncogenic fusion present in the patient offers an opportunity to treat the patient with inhibitors specific to the oncogenic fusion present in the patient.
This test provides fusion information for 151 gene fusion partners relevant to solid tumors, including those associated with soft tissue sarcomas (see below for the list of fusion partner genes included in this test):
ABL1, ABL2, ACVR2A, AKT1, AKT2, AKT3, ALK, AR, ARHGAP26, ARHGAP6, AXL, BCOR, BRAF, BRD3, BRD4, C11orf95, CAMTA1, CCNB3, CCND1, CD274, CIC,CREB3L2, CRTC1, CSF1, CSF1R, CTNNB1, DNAJB1, EGF, EGFR, EPC1, ERBB2, ERBB4, ERG, ESR1, ESRRA, ETV1, ETV4, ETV5, ETV6, EWSR1, FGF1, FGFR1, FGFR2, FGFR3, FGR, FOS, FOSB, FOXO1, FOXO4, FOXR2, FUS, GLI1, GRB7, HMGA2, HRAS, HTN3, IDH1, IDH2, IGF1R, INSR, JAK1, JAK2, JAK3, JAZF1, KIT, KRAS, MAML1, MAML2, MAML3, MAP2K1, MAST1, MAST2, MBTD1, MDM2, MEAF6 ,MET, MGEA5, MKL2, MN1, MSANTD3, MSMB, MUSK, MYB, MYBL1, MYC, MYOD1, NCOA1, NCOA2, NCOA3, NDRG1, NFATC2, NFE2L2, NFIB, NOTCH1, NOTCH2, NR4A3, NRAS, NRG1, NTRK1, NTRK2, NTRK3, NUMBL, NUTM1, PAX3, PAX7, PAX8, PDGFB, PDGFD, PDGFRA, PDGFRB, PHF1, PHKB, PIK3CA, PKN1, PLAG1, PPARG, PRDM10, PRKACA, PRKACB, PRKCA, PRKCB, PRKCD, PRKD1, PRKD2, PRKD3, QKI, RAD51B, RAF1, RELA, RET, ROS1, RSPO2, RSPO3, SETD2, SS18, SS18L1, STAT6, TAF15, TCF12, TERT, TFE3, TFEB, TFG, THADA, TMPRSS2, TTYH1, USP6, VGLL2, WWTR1, YAP1, YWHAE |
Positive results may be confirmed by RT-PCR with Sanger sequencing.
| Outpatient Requirements |
This test was discontinued on 7/6/2026 and replaced with Somatic Disease RNA Sequencing (test code: SDRNA). However, Solid Tumor Fusion Analysis is New York State Approved and may still be ordered for New York State patients. Please discuss with the laboratory if there are other testing needs related to this assay.
| Specimen Type | Type of Container | Volume of Specimen | Status |
|---|---|---|---|
| Tissue (Snap-frozen) | Tissue cassette | 50 mg | Preferred |
| Tissue (Snap-frozen) | Cryogenic tube | 50 mg | Alternate |
| OCT-embedded tissue | Tissue cassette | 50 mg | Preferred |
| OCT-embedded tissue | Cryogenic tube | 50 mg | Alternate |
| Paraffin embedded tissue | Paraffin block | Preferred | |
| Tissue (Fresh) | Tissue culture transport media | 50 mg | Preferred |
| Tissue (Fresh) | Sterile container with saline | 50 mg | Alternate |
| Tissue scrolls (FFPE) | Sterile container | Preferred | |
| Unstained tissue slides | Unstained slides and consecutive cut H&E | 10 slides, 10 microns thick | Alternate |
| RNA *Must be extracted in CLIA approved lab | Microcentrifuge tube | Contact IGM lab | Alternate |
If you are an external healthcare provider with no access to Nationwide Children’s Epic system, submission of a completed Oncology Genetic Test Requisition Form is required. If you are an internal ordering provider with access to Nationwide Children’s Epic system, no requisition form is required; please place the lab order electronically in Epic.
If submitting tissue scroll specimen, please use this Tissue Scroll Calculator tool to determine the thickness and number of tissue scrolls to send to the laboratory (approximately 300mm2 at 10 microns thickness).
SPECIMEN INFORMATION:
Fresh and snap-frozen tissue specimens must contain minimum of 10% tumor. Formalin-fixed paraffin embedded (FFPE) tissue block and FFPE tissue scroll specimens must contain minimum of 25% tumor. Please submit the pathology report from the submitted sample. Internal pathology review will also be performed to determine the tumor content in specimen.
If sending FFPE tissue scrolls, an H&E slide from a consecutive cut is also required. Please contact the laboratory at (614) 722-5321 to request the scroll calculator application to be emailed to you to determine the number of scrolls required.
All specimens must be labeled with a patient name and one other identifier (DOB, MRN, Specimen ID#, etc). Sample acquisition prior to receiving therapy is strongly preferred.
SPECIMEN SHIPPING:
Specimens must be shipped as soon as possible after collection due to time-sensitive specimen stability. Ship all samples via overnight courier. Whenever possible, send specimen immediately after collection. For fresh tumor tissue, ship the sample refrigerated using cold packs. If specimen cannot be sent on the collection date, then snap-freeze the tumor tissue immediately after collection and ship the sample frozen (bury the entire tissue in dry ice). Lab must receive specimen within 48 hours. FFPE tissue and FFPE tissue scrolls should be sent at room temperature via overnight shipping. Saturday deliveries are accepted; please check Saturday Delivery on shipment labels.
This test evaluates for the presence of oncogenic gene fusions in solid tumors. Gene fusions seen in cancers frequently involve tyrosine kinases where constitutive activation results in augmented downstream signaling and tumor proliferation. Targeted therapies directed at constitutively-activated oncogenic tyrosine kinases have been demonstrated to be effective against cancers with fusions involving certain genes, such as ALK, ROS1, PDGFB, RET, NTRK1, NTRK2, NTRK3, FGFR1, FGFR2, FGFR3, BRAF, and CRAF. Identifying a specific oncogenic fusion present in the patient offers an opportunity to treat the patient with inhibitors specific to the oncogenic fusion present in the patient.
This test provides fusion information for 151 gene fusion partners relevant to solid tumors, including those associated with soft tissue sarcomas (see below for the list of fusion partner genes included in this test):
ABL1, ABL2, ACVR2A, AKT1, AKT2, AKT3, ALK, AR, ARHGAP26, ARHGAP6, AXL, BCOR, BRAF, BRD3, BRD4, C11orf95, CAMTA1, CCNB3, CCND1, CD274, CIC,CREB3L2, CRTC1, CSF1, CSF1R, CTNNB1, DNAJB1, EGF, EGFR, EPC1, ERBB2, ERBB4, ERG, ESR1, ESRRA, ETV1, ETV4, ETV5, ETV6, EWSR1, FGF1, FGFR1, FGFR2, FGFR3, FGR, FOS, FOSB, FOXO1, FOXO4, FOXR2, FUS, GLI1, GRB7, HMGA2, HRAS, HTN3, IDH1, IDH2, IGF1R, INSR, JAK1, JAK2, JAK3, JAZF1, KIT, KRAS, MAML1, MAML2, MAML3, MAP2K1, MAST1, MAST2, MBTD1, MDM2, MEAF6 ,MET, MGEA5, MKL2, MN1, MSANTD3, MSMB, MUSK, MYB, MYBL1, MYC, MYOD1, NCOA1, NCOA2, NCOA3, NDRG1, NFATC2, NFE2L2, NFIB, NOTCH1, NOTCH2, NR4A3, NRAS, NRG1, NTRK1, NTRK2, NTRK3, NUMBL, NUTM1, PAX3, PAX7, PAX8, PDGFB, PDGFD, PDGFRA, PDGFRB, PHF1, PHKB, PIK3CA, PKN1, PLAG1, PPARG, PRDM10, PRKACA, PRKACB, PRKCA, PRKCB, PRKCD, PRKD1, PRKD2, PRKD3, QKI, RAD51B, RAF1, RELA, RET, ROS1, RSPO2, RSPO3, SETD2, SS18, SS18L1, STAT6, TAF15, TCF12, TERT, TFE3, TFEB, TFG, THADA, TMPRSS2, TTYH1, USP6, VGLL2, WWTR1, YAP1, YWHAE |
Positive results may be confirmed by RT-PCR with Sanger sequencing.
| Inpatient Requirements |
This test was discontinued on 7/6/2026 and replaced with Somatic Disease RNA Sequencing (test code: SDRNA). However, Solid Tumor Fusion Analysis is New York State Approved and may still be ordered for New York State patients. Please discuss with the laboratory if there are other testing needs related to this assay.
| Specimen Type | Type of Container | Volume of Specimen | Status |
|---|---|---|---|
| Tissue (Snap-frozen) | Tissue cassette | 50 mg | Preferred |
| Tissue (Snap-frozen) | Cryogenic tube | 50 mg | Alternate |
| OCT-embedded tissue | Tissue cassette | 50 mg | Preferred |
| OCT-embedded tissue | Cryogenic tube | 50 mg | Alternate |
| Paraffin embedded tissue | Paraffin block | Preferred | |
| Tissue (Fresh) | Tissue culture transport media | 50 mg | Preferred |
| Tissue (Fresh) | Sterile container with saline | 50 mg | Alternate |
| Tissue scrolls (FFPE) | Sterile container | Preferred | |
| Unstained tissue slides | Unstained slides and consecutive cut H&E | 10 slides, 10 microns thick | Alternate |
| RNA *Must be extracted in CLIA approved lab | Microcentrifuge tube | Contact IGM lab | Alternate |
| Specimen Type | Type of Container | Minimum Volume |
|---|---|---|
| Tissue (Snap-frozen) | Tissue cassette | |
| Tissue (Snap-frozen) | Cryogenic tube | |
| OCT-embedded tissue | Tissue cassette | |
| OCT-embedded tissue | Cryogenic tube | |
| Paraffin embedded tissue | Paraffin block | |
| Tissue (Fresh) | Tissue culture transport media | |
| Tissue (Fresh) | Sterile container with saline | |
| Tissue scrolls (FFPE) | Sterile container |
If you are an external healthcare provider with no access to Nationwide Children’s Epic system, submission of a completed Oncology Genetic Test Requisition Form is required. If you are an internal ordering provider with access to Nationwide Children’s Epic system, no requisition form is required; please place the lab order electronically in Epic.
If submitting tissue scroll specimen, please use this Tissue Scroll Calculator tool to determine the thickness and number of tissue scrolls to send to the laboratory (approximately 300mm2 at 10 microns thickness).
SPECIMEN INFORMATION:
Fresh and snap-frozen tissue specimens must contain minimum of 10% tumor. Formalin-fixed paraffin embedded (FFPE) tissue block and FFPE tissue scroll specimens must contain minimum of 25% tumor. Please submit the pathology report from the submitted sample. Internal pathology review will also be performed to determine the tumor content in specimen.
If sending FFPE tissue scrolls, an H&E slide from a consecutive cut is also required. Please contact the laboratory at (614) 722-5321 to request the scroll calculator application to be emailed to you to determine the number of scrolls required.
All specimens must be labeled with a patient name and one other identifier (DOB, MRN, Specimen ID#, etc). Sample acquisition prior to receiving therapy is strongly preferred.
SPECIMEN SHIPPING:
Specimens must be shipped as soon as possible after collection due to time-sensitive specimen stability. Ship all samples via overnight courier. Whenever possible, send specimen immediately after collection. For fresh tumor tissue, ship the sample refrigerated using cold packs. If specimen cannot be sent on the collection date, then snap-freeze the tumor tissue immediately after collection and ship the sample frozen (bury the entire tissue in dry ice). Lab must receive specimen within 48 hours. FFPE tissue and FFPE tissue scrolls should be sent at room temperature via overnight shipping. Saturday deliveries are accepted; please check Saturday Delivery on shipment labels.
This test evaluates for the presence of oncogenic gene fusions in solid tumors. Gene fusions seen in cancers frequently involve tyrosine kinases where constitutive activation results in augmented downstream signaling and tumor proliferation. Targeted therapies directed at constitutively-activated oncogenic tyrosine kinases have been demonstrated to be effective against cancers with fusions involving certain genes, such as ALK, ROS1, PDGFB, RET, NTRK1, NTRK2, NTRK3, FGFR1, FGFR2, FGFR3, BRAF, and CRAF. Identifying a specific oncogenic fusion present in the patient offers an opportunity to treat the patient with inhibitors specific to the oncogenic fusion present in the patient.
This test provides fusion information for 151 gene fusion partners relevant to solid tumors, including those associated with soft tissue sarcomas (see below for the list of fusion partner genes included in this test):
ABL1, ABL2, ACVR2A, AKT1, AKT2, AKT3, ALK, AR, ARHGAP26, ARHGAP6, AXL, BCOR, BRAF, BRD3, BRD4, C11orf95, CAMTA1, CCNB3, CCND1, CD274, CIC,CREB3L2, CRTC1, CSF1, CSF1R, CTNNB1, DNAJB1, EGF, EGFR, EPC1, ERBB2, ERBB4, ERG, ESR1, ESRRA, ETV1, ETV4, ETV5, ETV6, EWSR1, FGF1, FGFR1, FGFR2, FGFR3, FGR, FOS, FOSB, FOXO1, FOXO4, FOXR2, FUS, GLI1, GRB7, HMGA2, HRAS, HTN3, IDH1, IDH2, IGF1R, INSR, JAK1, JAK2, JAK3, JAZF1, KIT, KRAS, MAML1, MAML2, MAML3, MAP2K1, MAST1, MAST2, MBTD1, MDM2, MEAF6 ,MET, MGEA5, MKL2, MN1, MSANTD3, MSMB, MUSK, MYB, MYBL1, MYC, MYOD1, NCOA1, NCOA2, NCOA3, NDRG1, NFATC2, NFE2L2, NFIB, NOTCH1, NOTCH2, NR4A3, NRAS, NRG1, NTRK1, NTRK2, NTRK3, NUMBL, NUTM1, PAX3, PAX7, PAX8, PDGFB, PDGFD, PDGFRA, PDGFRB, PHF1, PHKB, PIK3CA, PKN1, PLAG1, PPARG, PRDM10, PRKACA, PRKACB, PRKCA, PRKCB, PRKCD, PRKD1, PRKD2, PRKD3, QKI, RAD51B, RAF1, RELA, RET, ROS1, RSPO2, RSPO3, SETD2, SS18, SS18L1, STAT6, TAF15, TCF12, TERT, TFE3, TFEB, TFG, THADA, TMPRSS2, TTYH1, USP6, VGLL2, WWTR1, YAP1, YWHAE |
Positive results may be confirmed by RT-PCR with Sanger sequencing.
| Overview/Billing |
| Interpretation |
This test evaluates for the presence of oncogenic gene fusions in solid tumors. Gene fusions seen in cancers frequently involve tyrosine kinases where constitutive activation results in augmented downstream signaling and tumor proliferation. Targeted therapies directed at constitutively-activated oncogenic tyrosine kinases have been demonstrated to be effective against cancers with fusions involving certain genes, such as ALK, ROS1, PDGFB, RET, NTRK1, NTRK2, NTRK3, FGFR1, FGFR2, FGFR3, BRAF, and CRAF. Identifying a specific oncogenic fusion present in the patient offers an opportunity to treat the patient with inhibitors specific to the oncogenic fusion present in the patient.
This test provides fusion information for 151 gene fusion partners relevant to solid tumors, including those associated with soft tissue sarcomas (see below for the list of fusion partner genes included in this test):
ABL1, ABL2, ACVR2A, AKT1, AKT2, AKT3, ALK, AR, ARHGAP26, ARHGAP6, AXL, BCOR, BRAF, BRD3, BRD4, C11orf95, CAMTA1, CCNB3, CCND1, CD274, CIC,CREB3L2, CRTC1, CSF1, CSF1R, CTNNB1, DNAJB1, EGF, EGFR, EPC1, ERBB2, ERBB4, ERG, ESR1, ESRRA, ETV1, ETV4, ETV5, ETV6, EWSR1, FGF1, FGFR1, FGFR2, FGFR3, FGR, FOS, FOSB, FOXO1, FOXO4, FOXR2, FUS, GLI1, GRB7, HMGA2, HRAS, HTN3, IDH1, IDH2, IGF1R, INSR, JAK1, JAK2, JAK3, JAZF1, KIT, KRAS, MAML1, MAML2, MAML3, MAP2K1, MAST1, MAST2, MBTD1, MDM2, MEAF6 ,MET, MGEA5, MKL2, MN1, MSANTD3, MSMB, MUSK, MYB, MYBL1, MYC, MYOD1, NCOA1, NCOA2, NCOA3, NDRG1, NFATC2, NFE2L2, NFIB, NOTCH1, NOTCH2, NR4A3, NRAS, NRG1, NTRK1, NTRK2, NTRK3, NUMBL, NUTM1, PAX3, PAX7, PAX8, PDGFB, PDGFD, PDGFRA, PDGFRB, PHF1, PHKB, PIK3CA, PKN1, PLAG1, PPARG, PRDM10, PRKACA, PRKACB, PRKCA, PRKCB, PRKCD, PRKD1, PRKD2, PRKD3, QKI, RAD51B, RAF1, RELA, RET, ROS1, RSPO2, RSPO3, SETD2, SS18, SS18L1, STAT6, TAF15, TCF12, TERT, TFE3, TFEB, TFG, THADA, TMPRSS2, TTYH1, USP6, VGLL2, WWTR1, YAP1, YWHAE |
Positive results may be confirmed by RT-PCR with Sanger sequencing.
| NCH Lab Only |
This test was discontinued on 7/6/2026 and replaced with Somatic Disease RNA Sequencing (test code: SDRNA). However, Solid Tumor Fusion Analysis is New York State Approved and may still be ordered for New York State patients. Please discuss with the laboratory if there are other testing needs related to this assay.
| Specimen Type | Type of Container | Volume of Specimen | Status |
|---|---|---|---|
| Tissue (Snap-frozen) | Tissue cassette | 50 mg | Preferred |
| Tissue (Snap-frozen) | Cryogenic tube | 50 mg | Alternate |
| OCT-embedded tissue | Tissue cassette | 50 mg | Preferred |
| OCT-embedded tissue | Cryogenic tube | 50 mg | Alternate |
| Paraffin embedded tissue | Paraffin block | Preferred | |
| Tissue (Fresh) | Tissue culture transport media | 50 mg | Preferred |
| Tissue (Fresh) | Sterile container with saline | 50 mg | Alternate |
| Tissue scrolls (FFPE) | Sterile container | Preferred | |
| Unstained tissue slides | Unstained slides and consecutive cut H&E | 10 slides, 10 microns thick | Alternate |
| RNA *Must be extracted in CLIA approved lab | Microcentrifuge tube | Contact IGM lab | Alternate |
| Specimen Type | Type of Container | Minimum Volume |
|---|---|---|
| Tissue (Snap-frozen) | Tissue cassette | |
| Tissue (Snap-frozen) | Cryogenic tube | |
| OCT-embedded tissue | Tissue cassette | |
| OCT-embedded tissue | Cryogenic tube | |
| Paraffin embedded tissue | Paraffin block | |
| Tissue (Fresh) | Tissue culture transport media | |
| Tissue (Fresh) | Sterile container with saline | |
| Tissue scrolls (FFPE) | Sterile container |
If you are an external healthcare provider with no access to Nationwide Children’s Epic system, submission of a completed Oncology Genetic Test Requisition Form is required. If you are an internal ordering provider with access to Nationwide Children’s Epic system, no requisition form is required; please place the lab order electronically in Epic.
If submitting tissue scroll specimen, please use this Tissue Scroll Calculator tool to determine the thickness and number of tissue scrolls to send to the laboratory (approximately 300mm2 at 10 microns thickness).
SPECIMEN INFORMATION:
Fresh and snap-frozen tissue specimens must contain minimum of 10% tumor. Formalin-fixed paraffin embedded (FFPE) tissue block and FFPE tissue scroll specimens must contain minimum of 25% tumor. Please submit the pathology report from the submitted sample. Internal pathology review will also be performed to determine the tumor content in specimen.
If sending FFPE tissue scrolls, an H&E slide from a consecutive cut is also required. Please contact the laboratory at (614) 722-5321 to request the scroll calculator application to be emailed to you to determine the number of scrolls required.
All specimens must be labeled with a patient name and one other identifier (DOB, MRN, Specimen ID#, etc). Sample acquisition prior to receiving therapy is strongly preferred.
SPECIMEN SHIPPING:
Specimens must be shipped as soon as possible after collection due to time-sensitive specimen stability. Ship all samples via overnight courier. Whenever possible, send specimen immediately after collection. For fresh tumor tissue, ship the sample refrigerated using cold packs. If specimen cannot be sent on the collection date, then snap-freeze the tumor tissue immediately after collection and ship the sample frozen (bury the entire tissue in dry ice). Lab must receive specimen within 48 hours. FFPE tissue and FFPE tissue scrolls should be sent at room temperature via overnight shipping. Saturday deliveries are accepted; please check Saturday Delivery on shipment labels.
This test evaluates for the presence of oncogenic gene fusions in solid tumors. Gene fusions seen in cancers frequently involve tyrosine kinases where constitutive activation results in augmented downstream signaling and tumor proliferation. Targeted therapies directed at constitutively-activated oncogenic tyrosine kinases have been demonstrated to be effective against cancers with fusions involving certain genes, such as ALK, ROS1, PDGFB, RET, NTRK1, NTRK2, NTRK3, FGFR1, FGFR2, FGFR3, BRAF, and CRAF. Identifying a specific oncogenic fusion present in the patient offers an opportunity to treat the patient with inhibitors specific to the oncogenic fusion present in the patient.
This test provides fusion information for 151 gene fusion partners relevant to solid tumors, including those associated with soft tissue sarcomas (see below for the list of fusion partner genes included in this test):
ABL1, ABL2, ACVR2A, AKT1, AKT2, AKT3, ALK, AR, ARHGAP26, ARHGAP6, AXL, BCOR, BRAF, BRD3, BRD4, C11orf95, CAMTA1, CCNB3, CCND1, CD274, CIC,CREB3L2, CRTC1, CSF1, CSF1R, CTNNB1, DNAJB1, EGF, EGFR, EPC1, ERBB2, ERBB4, ERG, ESR1, ESRRA, ETV1, ETV4, ETV5, ETV6, EWSR1, FGF1, FGFR1, FGFR2, FGFR3, FGR, FOS, FOSB, FOXO1, FOXO4, FOXR2, FUS, GLI1, GRB7, HMGA2, HRAS, HTN3, IDH1, IDH2, IGF1R, INSR, JAK1, JAK2, JAK3, JAZF1, KIT, KRAS, MAML1, MAML2, MAML3, MAP2K1, MAST1, MAST2, MBTD1, MDM2, MEAF6 ,MET, MGEA5, MKL2, MN1, MSANTD3, MSMB, MUSK, MYB, MYBL1, MYC, MYOD1, NCOA1, NCOA2, NCOA3, NDRG1, NFATC2, NFE2L2, NFIB, NOTCH1, NOTCH2, NR4A3, NRAS, NRG1, NTRK1, NTRK2, NTRK3, NUMBL, NUTM1, PAX3, PAX7, PAX8, PDGFB, PDGFD, PDGFRA, PDGFRB, PHF1, PHKB, PIK3CA, PKN1, PLAG1, PPARG, PRDM10, PRKACA, PRKACB, PRKCA, PRKCB, PRKCD, PRKD1, PRKD2, PRKD3, QKI, RAD51B, RAF1, RELA, RET, ROS1, RSPO2, RSPO3, SETD2, SS18, SS18L1, STAT6, TAF15, TCF12, TERT, TFE3, TFEB, TFG, THADA, TMPRSS2, TTYH1, USP6, VGLL2, WWTR1, YAP1, YWHAE |
Positive results may be confirmed by RT-PCR with Sanger sequencing.
